About WaferGen
WaferGen is a Healthcare company based in Fremont (United States) founded in 2002, and was acquired by Takara Bio in May 2016. Genomic tools are provided for resequencing, genotyping, and expression analysis. WaferGen offers products and services including Biotech Kits, Reagents, and Instruments. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Suite. Its legal entity is Takara Bio USA, Inc. Its competitors include Arbor Biotechnologies, Octant and Factor Bioscience; 3 of its 3 listed competitors have raised funding.
Company details
WaferGen offers a set of tools for molecular and single-cell analysis in the life sciences, pharmaceutical, and clinical laboratory industries. Its products include ICELL8 Single-Cell System (for single-cell research); NGS Library Prep system, SmartChip NGS Target Enrichment System and Real-Time PCR System. It also provides chips, printed panels, primers and reagent kits for Single Cell Analysis, NGS Sample Prep, and Clinical Research.
- Headquarters Fremont, United States
- Stage Acquired
- SectorsHealthcare
- Website wafergen.com
- Social LinkedIn X
- Acquired by Takara Bio (May 2016)
- Legal Name Takara Bio Usa, Inc.
- Latest Funding Round$510K (USD), Post-IPO
Aug 2014
- InvestorsTakara Bio
& 4 more
- Acquired byTakara Bio
(May 2016)
Products & Services of WaferGen
WaferGen offers a comprehensive portfolio of products and services, including Biotech Kits, Reagents, and Instruments.
Kits for gene discovery and nucleic acid purification
Reagents for PCR and gene editing processes
Instruments for single-cell sequencing and analysis
Funding Insights of WaferGen
- Total Rounds 10
- Last Round Post-IPO — $510,000
- First Round $10.7M
(May 2007)
- Investors Count 4
All 10 funding rounds of WaferGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2014 | $510,000 | Post-IPO | – | – | – |
| Sep 2013 | $13.67M | Post-IPO | – | – | – |
| Sep 2013 | $15.04M | Post-IPO | – | – | – |
| May 2011 | $30.55M | Post-IPO | – | – | |
| Dec 2010 | $2M | Debt – Conventional | – | – | |
| Feb 2010 | $5.09M | Post-IPO | – | – | – |
| Sep 2009 | $6.26M | Post-IPO | – | – | – |
| Jun 2008 | $3.56M | Post-IPO | – | – | – |
| Jun 2007 | $12M | Post-IPO | – | – | – |
| May 2007 | $10.7M | Post-IPO | – | – | – |
5 investors in total: 5 institutional.
Investors in WaferGen
WaferGen has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Takara Bio, Oxford Finance and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
| merlinnexus.com | ||||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Developer of gene-based therapies as well as contract services for the industrial and agricultural sector | 1925 | takara-bio.com | Frankfurt, Germany |
Investor details for WaferGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of WaferGen
5 dated milestones of WaferGen across 14 years, from founding to its latest funding, stage changes and deals.
- Founded WaferGen is founded.
- Funding First funding round of $10.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $510K.
- Exit Acquired by Takara Bio.
Competitors of WaferGen
WaferGen has 3 listed competitors in our database, 3 of them funded. They include Arbor Biotechnologies, Octant and Factor Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| arbor.bio | 2016 | Cambridge, United States | $304.1M | 117 | Genomic technologies and drug discovery platforms are provided. | |
| octant.bio | 2017 | Los Angeles, United States | $110M | 63 | Human cell interaction platform is provided for drug discovery. | |
| factor.bio | 2011 | Cambridge, United States | $1M | Genomic technologies are developed to treat diseases and enhance health. |
Detailed competitors of WaferGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of WaferGen
Websites that share an audience with WaferGen (wafergen.com).
Websites whose visitors overlap most with WaferGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| regulusrx.com | 100% | View details | |||
pictar.mdc-berlin.de | pictar.mdc-berlin.de | 99% | – | ||
targetscan.org | targetscan.org | 99% | #1,696,031 | – | |
origene.com.cn | origene.com.cn | 99% | – | ||
| exiqon.com | 99% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for WaferGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as WaferGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about WaferGen
WaferGen was founded in 2002 and raised its 1st funding round 5 years after it was founded.
WaferGen is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
WaferGen offers a set of tools for molecular and single-cell analysis in the life sciences, pharmaceutical, and clinical laboratory industries. Its products include ICELL8 Single-Cell System (for single-cell research); NGS Library Prep system, SmartChip NGS Target Enrichment System and Real-Time PCR System. It also provides chips, printed panels, primers and reagent kits for Single Cell Analysis, NGS Sample Prep, and Clinical Research.
WaferGen's top competitors include Arbor Biotechnologies, Octant and Factor Bioscience.
WaferGen offers Biotech Kits, Reagents, and Instruments.
WaferGen has 5 investors. Key investors include Takara Bio, Oxford Finance, Great Point Partners, Deerfield, and Merlin Nexus.
WaferGen operates through Takara Bio Usa, Inc..
Yes. WaferGen was acquired by Takara Bio in May 2016.